Vanadate as an oral antidiabetic agent

References

• GERICH JE: Oral hypoglycemic agents. N. Engl. J. Med.(1989) 321(18):1231–1245.
   PubMed Web of Science ®Google Scholar
• THE DIABETES CONTROL AND COMPLICATIONS TRIALRESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mel-litus. N. Engl. J. Med. (1993) 329:977–986.
   PubMed Web of Science ®Google Scholar
• WITCHER JW: Implications of the DCCT. A pharmaceu-tical industry viewpoint and commentary. Diabetes Re-views (1994) 2(3):272–276.
   Google Scholar
• STERN A, YIN X, TSANG S-S, DAVISON A, MOON J: Vana-dium as a modulator of cellular regulatory cascades and oncogene expression. Biochem. Cell Biol. (1993) 71:103–112.
   PubMed Web of Science ®Google Scholar
• NIELSON FH: Nutritional requirements for boron, sili-con, vanadium, nickel, and arsenic: Current knowledge and speculation FASEB J (1991) 5:2661–2667.
   Google Scholar
• BRICHARD SM, LEDERER J, HENQUIN JC: The insulin-like properties of vanadium: A curiosity or a perspective for the treatment of diabetes? Diabetes Metab. (1991) 17:435–440.
   Google Scholar
• Good review on the glucose lowering effects of vanadate in diabetic rodent models.
   Google Scholar
• POSNER BI, SHAVER A, FANTUS IG: Insulin mimetic agents: Vanadium and peroxovanadium compounds. In: New ant idiabetic drugs(1990). Bailey C and Flatt P, (Eds)., Smith-Gordon, London. p. 107–118.
   Google Scholar
• SHECHTER Y: Insulin-mimetic effects of vanadate. Dia- betes (1990) 39:1–5.
   PubMed Web of Science ®Google Scholar
• CROS G, MONGOLD J, SERRANO J, RAMANADHAM S, MCNEILL JH: Effects of vanadyl derivatives on animal models of diabetes. Mol. Cell. Biochem. (1992) 109:163–166.
   PubMed Web of Science ®Google Scholar
• TAMURA S, BROWN TA, WHIPPLE JH, FUJITA-YAMAGUCHI Y, DUBLER RE, CHENG K, LARNER J: A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes J. Biol. Chem. (1984) 259:6650–6658
   Web of Science ®Google Scholar
• GREEN A: The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insu-lin-receptor level Biochem.J. (1986) 238:663–669.
   Google Scholar
• ROSEN OM: After insulin binds. Science (1987) 237:1452–1458.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN BJ: Protein-tyrosine phosphatases and the regulation of insulin action. J. Cell. Biochem. (1992) 48:33–42.
   PubMed Web of Science ®Google Scholar
• HE14-ETZ D, RUTTER WJ, ZICK Y: The insulinomimetic agents 11202 and vanadate stimulate tyrosine phospho-rylation of potential target proteins for the insulin receptor kinase in intact cells Biochem.J. (1992) 288:631–635.
   Google Scholar
• ELBERG G, LI J, SHECHTER Y: Vanadium activates or inhibits receptor and non-receptor protein tyrosine kinases in cell-free experiments, depending on its oxi-dation state J. Biol. Chem. (1994) 269:9521–9527.
   Web of Science ®Google Scholar
• Paper shows different intracellular chemical forms of vanadate to be selective for certain receptor and post-receptor steps in the insulin signal transduction cascade.
   Google Scholar
• POSNER BI, FAURE R, BURGESS JW, BEVAN AP, LACHANCE D, ZHANG-SUN G, FANTUS IG, NG JB, HALL DA, LUM BS,SHAVER A: Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetic& J. Biol. Chem. (1994) 269:4596–4604.
   Google Scholar
• Study shows that vanadium analogues have in vitro selectivity against PTPases.
   Google Scholar
• HEYLIGER CE, TAHILIANI AG, MCNEILL JH: Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science (1985) 227:1474–1477.
   PubMed Web of Science ®Google Scholar
• DOMINGO J1L, GOMEZ M, LLOBET JM, CORBELLA J, KEENCL: Oral vanadium administration to streptozotocin-diabetic rats has marked negative side-effects which are Independent of the form of vanadium used. Toxicology (1991) 66:279–287.
   PubMed Web of Science ®Google Scholar
• DETATA V, NOVELLI M, CAVALLINI G, MASIELLO P, GORI Z, BERGAMINI E: Beneficial effects of the oral admini- stration of vanadyl sulphate on glucose metabolism in senescent rats. J. Gerontol. (1993) 48(5):B191–B195,
   PubMedGoogle Scholar
• DAI S, THOMPSON KH, MCNEILL JH: One-year treatment of streptozotocin-induced diabetic rats with vanadyl sulfate. Pharmacology & Toxicology (1994) 74:101–109.
   PubMedGoogle Scholar
• CRANS DC: Aqueous chemistry of labile oxovanadates: relevance to biological studies. Comments Inorg. Chem. (1994) 16(1 & 2)1–33.
   Google Scholar
• Thorough review on the complex chemical properties of vanadate.
   Google Scholar
• LIOCHEV SI, FRIDOVICH I: Vanadate-stimulated oxida-tion of NAD(P)H in the presence of biological mem-branes and other sources of 02. Arch. Biochem. Biophys. (1990) 279(1):1–7.
   PubMed Web of Science ®Google Scholar
• FURUYOSHI S, OKUYAMA K, NAGATSUKA M, KAWABATAN: Stannum (IV) chloride stimulates vanadium (IV) catalyzed oxidation of NAD11 J. Biochem. (1993) 113:508–512.
   Google Scholar
• LONNROTH P, ERIKSSON JW, POSNER BI, SMITH U: Per- oxovanadate but not vanadate exerts insulin-like effects In human adipocytes Diabetologia (1993) 36(2):113–116. Study demonstrating that vanadate effectiveness may be species dependent.
   Google Scholar
• MONGOLD JJ, CROS GH, VIAN L, TEP A, RAMANADHAM S, SIOU G, DIAZ J, MCNEILL JH, SERRANO JJ: Toxicological aspects of vanadyl sulphate on diabetic rats: Effects on vanadium level and pancreatic B-cell morphology Pharmacology and Toxicology (1990) 67:192–198.
   Google Scholar
• LEONARD A, GERBER GB: Mutagenicity, carcinogenicityand teratogenicity of vanadium compounds. Mutation Res. (1994) 317:81–88.
   PubMed Web of Science ®Google Scholar
• SAKURAI H, TSUCHIYA K, NUKATSUKA M, KAWADA J,ISHIKAWA S, YOSHIDA H, KOMATSU M: Insulin-mimetic action of vanadyl complexes. J. din. Biochem. Nutr. (1990) 8:193–200.
   Web of Science ®Google Scholar
• MCNEILL JH, YUEN VG, HOVEYDA HR, ORVIG C: Bis(mal- tolato)oxovanadium (IV) is a potent insulin mimetic J. Med. Chem. (1992) 35:1489–1491.
   Web of Science ®Google Scholar
• A vanadium analogue that is better absorbed and less toxic is described.
   Google Scholar
• ROSSETTI L, COHEN N, HALBERSTAM M, SHLIMOVICH P, HU M, SHAMOON H: In vivo metabolic effects of vana-dium on skeletal muscle and hepatic glucose metabo-lism Can. J. Physiol. Pharm. (1994) 72(S3):11.
   Google Scholar
• Preliminary abstract from the three week clinical trial in NIDDM subjects.
   Google Scholar
• GOLDFINE AB, FOLLI F, PATTI ME, SIMONSON DC, KAHN CR: Clinical trials of vanadium compounds in humandiabetes mellitus Can.J. Physiol. Pharrn. (1994) 72(53):11. Preliminary abstract from the two week clinical trial in IDDM and NIDDM subjects.
   Google Scholar